Introduction
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer.
Transient response to radiotherapy, ineffective chemotherapy and aggressive biology lead to rapid progression and a poor prognosis [1] [2] [3] . The glycosaminoglycan hyaluronan (HA) is a major component in extracellular matrices. CD44 and receptor for HA-mediated motility (RHAMM), two main cell surface HA-receptors, have been reported to play important roles in tumor invasion, proliferation, adhesion and migration [4] [5] [6] . Overexpression of CD44 and RHAMM has been detected in supratentorial gliomas [5, 6] . However, the expression of CD44 and RHAMM in DIPG, a disease entity distinct from supratentorial gliomas [1, 3] , has received little attention. In this study, we are aiming to compare the expression levels of CD44 and RHAMM, in surgical samples of DIPG with those in non-diffused brainstem glioma (NDBS).
Methods
Patients were included into DIPG group when preoperative MRI showed that the tumor was poorly demarcated and occupied >50% of the brainstem diameter [7] , while NDBG group consisted of patients with focal or exophytic brainstem gliomas. The diagnosis 
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Methods: Expression of CD44 and RHAMM mRNA in DIPG compared with nondiffused brainstem glioma (NDBS) was confirmed by real-time-PCR of 8 DIPG specimens and 6 NDBS specimens while Western blot of 15 DIPG specimens and 3 NDBS specimens was performed to detect the expression of CD44 and RHAMM protein in DIPG compared with NDBS.
Results:
Results of qPCR and Western blot showed that difference in expression levels of CD44 between DIPG and NDBG were not significant while RHAMM expression levels in DIPG group is significantly higher than in NDBG group. CD44 and RHAMM were detected by the affinity purified anti-CD44 and RHAMM antibody, respectively. Actin served as a control.
Conclusion
The t test was utilized to compare the continuous variables in the two independent groups. Histogram was utilized to demonstrate graphical visualization of the continuous variables. All statistical analyses were performed using the SPSS software version 22.0. P values < 0.05 were considered statistically significant, and those < 0.01 highly significant.
Results
There was no statistically significant difference in expression values of CD44 mRNA between two groups (p = 0.391, t test).
However, RHAMM mRNA expression levels in DIPG group is significantly higher than in NDBG group [mean ± SD (standard deviation), 3.31 ± 1.68 vs 1.18 ± 0.16, respectively, p = 0.009, t test] Figure 1A .
The relative expression of CD44 and RHAMM on the protein levels in DIPG and NDBG was examined by western blot. It was found that the expression levels of CD44 in DIPG and NDBG were similar (p = 0.708, t test) while DIPG had higher levels of RHAMM protein compared to NDBG (mean ± SD, 0.52±0.16 vs 0.24±0.13, respectively, p = 0.013, t test) Figures 1B and 2 . 
Discussion and Conclusion
In this study, we found that the expression levels of CD44 in DIPG and those in NDBG were similar while RHAMM was overexpressed in DIPG. In contrast to NDBG, DIPG has diffuse growth pattern and can hardly be surgically removed [1, 3] , which contributes to the dismal prognosis. It has been reported that RHAMM may play a more important role in cell migration than CD44 and that blocking RHAMM-HA interactions results in an inhibition of tumor cell migration and proliferation [6] . Under homeostatic condition, the expression of RHAMM is very low, which makes it a suitable target for cancer therapy with low toxicity [4] . RHAMM-based therapies, including RHAMM-R3 peptides and the combination of RHAMM-R3 and cell-based strategies have shown efficacy and low toxicity in patients with cancer [4, 8, 9] . Our study showed that the expression levels of CD44 in DIPG and NDBG were similar while RHAMM was overexpressed in DIPG, which might give promise of a novel therapeutic target for the treatment of this fatal disease. Obviously, further studies should be carried out to investigate the RHAMM signaling in DIPG and assess the effect of RHAMM-based therapies on DIPG.
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